ArticleJournal of bone oncology2024

Novel lipid metabolism factor HIBCH inhibitor synergizes with doxorubicin to suppress osteosarcoma growth and impacts clinical prognosis in osteosarcoma patients.

Xuhui Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.